Comparative Pharmacology
Head-to-head clinical analysis: CEFTAROLINE FOSAMIL versus KEFLEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFTAROLINE FOSAMIL versus KEFLEX.
CEFTAROLINE FOSAMIL vs KEFLEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ceftaroline fosamil is a prodrug that is converted to the active metabolite ceftaroline. Ceftaroline inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), including PBP2a in MRSA and PBP2x in Streptococcus pneumoniae, thereby preventing cross-linking of peptidoglycan.
Cephalexin is a first-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
600 mg IV every 12 hours infused over 1 hour
250-500 mg orally every 6 hours; maximum 4 g/day.
None Documented
None Documented
Terminal elimination half-life is approximately 2.6 hours in patients with normal renal function. This supports twice-daily dosing in most infections.
0.5–1.2 hours in patients with normal renal function (CrCl >50 mL/min); prolonged to >20 hours in ESRD.
Renal excretion of unchanged ceftaroline accounts for approximately 88% of the administered dose. Biliary/fecal elimination is minimal (<6%).
Primarily renal (90% or more unchanged via glomerular filtration and tubular secretion); small amounts biliary/fecal (<5%).
Category A/B
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic